Patrick A. Mayes

3.9k total citations · 1 hit paper
31 papers, 2.5k citations indexed

About

Patrick A. Mayes is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Patrick A. Mayes has authored 31 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Molecular Biology and 8 papers in Cancer Research. Recurrent topics in Patrick A. Mayes's work include Cancer Immunotherapy and Biomarkers (9 papers), Cancer, Hypoxia, and Metabolism (8 papers) and CAR-T cell therapy research (6 papers). Patrick A. Mayes is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Cancer, Hypoxia, and Metabolism (8 papers) and CAR-T cell therapy research (6 papers). Patrick A. Mayes collaborates with scholars based in United States, United Kingdom and France. Patrick A. Mayes's co-authors include Axel Hoos, Wafik S. El‐Deiry, Kenneth W. Hance, John M. Maris, David T. Dicker, Kageaki Kuribayashi, M. Celeste Simon, Nicolas Skuli, Guoliang Qing and Gabriel Krigsfeld and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Patrick A. Mayes

29 papers receiving 2.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

2014 375 citations Patrick A. Mayes, Jenny Craigen et al. Blood profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Patrick A. Mayes	1.4k	1.2k	586	521	381	31	2.5k
Ricardo M. Attar	1.7k 1.3×	877 0.7×	395 0.7×	652 1.3×	269 0.7×	72	3.2k
Laura Soucek	3.7k 2.7×	1.7k 1.5×	855 1.5×	858 1.6×	225 0.6×	54	5.0k
Erwin R. Boghaert	1.2k 0.9×	1.0k 0.9×	245 0.4×	196 0.4×	370 1.0×	58	2.5k
Mari Iida	1.5k 1.1×	1.3k 1.1×	456 0.8×	429 0.8×	59 0.2×	62	2.8k
Seth A. Ettenberg	2.8k 2.1×	1.9k 1.6×	1.0k 1.8×	544 1.0×	292 0.8×	44	4.2k
Suzanne Schubbert	1.7k 1.2×	736 0.6×	540 0.9×	223 0.4×	188 0.5×	22	2.3k
Tsutomu Kawaguchi	2.1k 1.5×	896 0.8×	479 0.8×	1.6k 3.1×	76 0.2×	137	3.8k
Igor Astsaturov	1.2k 0.9×	1.1k 1.0×	339 0.6×	512 1.0×	52 0.1×	97	2.7k
Joseph Gera	2.4k 1.8×	592 0.5×	376 0.6×	396 0.8×	474 1.2×	60	3.0k
Ralf Brandt	1.9k 1.4×	2.5k 2.1×	526 0.9×	381 0.7×	72 0.2×	27	4.0k

Countries citing papers authored by Patrick A. Mayes

Since Specialization

Citations

This map shows the geographic impact of Patrick A. Mayes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick A. Mayes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick A. Mayes more than expected).

Fields of papers citing papers by Patrick A. Mayes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick A. Mayes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick A. Mayes. The network helps show where Patrick A. Mayes may publish in the future.

Co-authorship network of co-authors of Patrick A. Mayes

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick A. Mayes. A scholar is included among the top collaborators of Patrick A. Mayes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick A. Mayes. Patrick A. Mayes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Qian, Shiquan, Cheng‐Tsung Lai, Kelly Federowicz, et al.. (2025). Discovery of Fluoroalkenes as Dual Inhibitors of Diacylglycerol Kinases Alpha and Zeta (DGKα/ζ). Journal of Medicinal Chemistry. 68(19). 20789–20813.

Piha‐Paul, Sarina A., et al.. (2022). 723 A phase 1, first-in-human, open-label, multicenter study of INCA32459, a bispecific anti–PD1 and anti–LAG-3 antibody, in patients with select advanced malignancies. Regular and Young Investigator Award Abstracts. A756–A756. 1 indexed citations

de, Rocío Montes, Sabyasachi Bhattacharya, Laura Seestaller‐Wehr, et al.. (2019). PF558 THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY. HemaSphere. 3(S1). 231–231. 14 indexed citations

Brett, Sara, Sapna Yadavilli, Laura Seestaller‐Wehr, et al.. (2018). Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. Annals of Oncology. 29. viii652–viii653. 1 indexed citations

Mayes, Patrick A., Kenneth W. Hance, & Axel Hoos. (2018). The promise and challenges of immune agonist antibody development in cancer. Nature Reviews Drug Discovery. 17(7). 509–527. 276 indexed citations

Angevin, Eric, Todd M. Bauer, Catherine Ellis, et al.. (2017). Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors. Cancer Research. 77(13_Supplement). CT039–CT039. 7 indexed citations

Yadavilli, Sapna, Tianqian Zhang, Ashleigh Hahn, et al.. (2017). Abstract 1637: ICOS agonism induces potent immune activation and anti-tumor response in non-clinical models. Cancer Research. 77(13_Supplement). 1637–1637. 2 indexed citations

Lee, Lydia, Jennifer C. Paterson, Gaëlle Herledan, et al.. (2016). Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. British Journal of Haematology. 174(6). 911–922. 132 indexed citations

Liu, Li, Patrick A. Mayes, Stephen D. Eastman, et al.. (2015). The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. Clinical Cancer Research. 21(7). 1639–1651. 352 indexed citations

10.

Allen, Joshua E., Gabriel Krigsfeld, Luv Patel, et al.. (2015). Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Molecular Cancer. 14(1). 99–99. 77 indexed citations

11.

Yong, Kwee, Fiona Germaschewski, Manuel Rodriguez‐Justo, et al.. (2013). Evaluation Of Bcma As a Therapeutic Target In Multiple Myeloma Using An Antibody-Drug Conjugate. Blood. 122(21). 4447–4447. 8 indexed citations

12.

Mayes, Patrick A., Yan Degenhardt, Andrew Wood, et al.. (2012). Mitogen‐activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere‐associated protein E inhibition. International Journal of Cancer. 132(3). 16 indexed citations

13.

Qing, Guoliang, Bo Li, Annette Vu, et al.. (2012). ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation. Cancer Cell. 22(5). 631–644. 303 indexed citations

14.

Mayes, Patrick A., Nathan G. Dolloff, Colin J. Daniel, et al.. (2011). Overcoming Hypoxia-Induced Apoptotic Resistance through Combinatorial Inhibition of GSK-3β and CDK1. Cancer Research. 71(15). 5265–5275. 27 indexed citations

15.

Dolloff, Nathan G., Patrick A. Mayes, Lori S. Hart, et al.. (2011). Off-Target Lapatinib Activity Sensitizes Colon Cancer Cells Through TRAIL Death Receptor Up-Regulation. Science Translational Medicine. 3(86). 86ra50–86ra50. 35 indexed citations

16.

Qing, Guoliang, Nicolas Skuli, Patrick A. Mayes, et al.. (2010). Combinatorial Regulation of Neuroblastoma Tumor Progression by N-Myc and Hypoxia Inducible Factor HIF-1α. Cancer Research. 70(24). 10351–10361. 128 indexed citations

17.

Balamuth, Naomi, Andrew Wood, Qun Wang, et al.. (2010). Serial Transcriptome Analysis and Cross-Species Integration Identifies Centromere-Associated Protein E as a Novel Neuroblastoma Target. Cancer Research. 70(7). 2749–2758. 41 indexed citations

18.

Kuribayashi, Kageaki, Gabriel Krigsfeld, Wenge Wang, et al.. (2008). TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biology & Therapy. 7(12). 2034–2038. 90 indexed citations

19.

Kuribayashi, Kageaki, Patrick A. Mayes, & Wafik S. El‐Deiry. (2006). What are caspases 3 and 7 doing upstream of the mitochondria?. Cancer Biology & Therapy. 5(7). 763–765. 119 indexed citations

20.

Mayes, Patrick A., et al.. (2005). Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biology & Therapy. 4(10). 1068–1074. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact